New China Innovation Policies Having Unintended Consequences?
This article was originally published in PharmAsia News
Executive Summary
Recent media coverage of “failed” drugs being given a second life in China has raised a raft of issues, including whether preference should be given to the domestic industry, with its poor quality record and scant innovation, and if the impact of the recent official redefinition of a new drug is really spurring innovation or just driving new types of licensing deals.